Recent Finacing
Recent Raise
Sublimity Therapeutics is a specialty pharma developing STI-0529, an oral colon-targeted cyclosporine for ulcerative colitis, advancing to global Phase 2b and collaborating with Dr. Falk Pharma.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Sublimity Therapeutics.
